Nurix will receive a $15 million extension fee and remains eligible for up to $73.5 million in preclinical milestones and potential future licensing payments.
GS-1811 is a potentially first-in-class immunotherapy designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory cells in tumors.
Veklury (remdesivir) with sales of $829 million offsets loss of exclusivity of Truvada and Atripla in the U.S. with sales down 72% and 42%, respectively.
Phase II trial to investigate Novo’s semaglutide and a combination of Gilead’s cilofexor and firsocostat, alone and in combination in cirrhosis due to NASH.